Skip to main content

The Delhi High Court granted an ex parte interim injunction restraining the defendants from marketing VARDENAFIL and VARDENAFIL HYDROCHLORIDE in India.

The court noted that the defendants product contained the plaintiff Bayer’s patented pharmaceutical preparation, but without its permission to exploit the same. The defendants’ drugs, though not commercially launched in India, were being exported to other countries.

Bayer initiated legal proceedings in India upon learning that drugs infringing its patent, valid till 2018, had been seized by customs authorities in Latvia.

Bayer Intellectual Property GmbH v Vipro Lifescience and anr.

Most Recent

News & Insights

VIEW ALL
Thought Leadership
•
Oct 15, 2026

First published on Enterprise IT World. Authored by Subroto Kumar Panda Imagine you gave a supersmart robot a credit card and told it to “buy the best

Taming the AI Beast: How Big Companies Build Safe AI Agents
News & Updates, Thought Leadership
•
Oct 14, 2026

Think about the last YouTube video you watched. It might have been a travel vlog, a product review, a legal explainer, a cooking tutorial or a short documentary.

Who Owns a YouTube Video? Copyright Protection for Digital Creators in India
News & Updates, Thought Leadership
•
Oct 09, 2026

For a creator, the product and the person are often indistinguishable. A finance educator’s credibility, a teacher’s cadence, a comedian’s

When Your Persona Becomes Your Business: Personality Rights of Influencers in India
News & Updates, Thought Leadership
•
Oct 06, 2026

A D2C brand can begin with little more than a name, a logo, a product page and an Instagram account. Then something changes. Customers begin recognising

Your Brand is More Than a Name: Brand Protection for D2C Startups in India